MktsMarkets

Traws Pharma, Inc.
NASDAQ: TRAWKey statistics
TRAW News
Stories mentioning TRAW from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 2,733 | 57.00 | 56.00 | 57.00 | 57.00 | |||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | ||||||
| Operating Expenses | ||||||||
| Research & Development | 4,912 | 2,506 | ||||||
| Sales General & Admin | ||||||||
| Total Operating Expenses | 6,946 | 7,368 | 4,055 | 3,982 | 5,260 | 5,334 | 8,593 | 123,405 |
| Operating Income (Loss) | (6,946) | (7,368) | (4,055) | (1,249) | (5,203) | (5,278) | (8,536) | (123,348) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | (2.00) | 14.00 | 96.00 | 188.00 | 180.00 | (206.00) | 61.00 | 205.00 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (7,107) | (7,443) | (3,962) | (915.00) | 21,490 | (29,922) | (8,475) | (123,143) |
| Earnings Per Share (Basic) | (0.53) | (0.90) | (0.34) | (0.11) | 2.17 | (19.27) | (1.49) | (20.52) |
| Earnings Per Share (Diluted) | (0.53) | (0.89) | (0.34) | (0.11) | 2.09 | (19.27) | (1.49) | (20.52) |
| Weighted Average Shares Outstanding (Basic) | 10,641 | 8,228 | 8,819 | 5,821 | 6,966 | 1,553 | 962.00 | 1,012 |
| Weighted Average Shares Outstanding (Diluted) | 10,641 | 8,376 | 8,819 | 5,821 | 7,215 | 1,553 | 962.00 | 1,012 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About TRAW
Traws Pharma, Inc. (NASDAQ: TRAW) is a stock listed on the Nasdaq Stock Market under the ticker symbol TRAW. It last traded at $0.2200 (Nov 6, 2026, 4:00 PM ET), up 0.8% on the day. That gives Traws Pharma a market capitalisation of $3.4M.
Over the past 52 weeks TRAW has traded between $0.2200 and $3.23.
For the quarter ended Mar 31, 2026 it reported a net loss of $7.1M.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | — | -$7.1M | — |
| Dec 31, 2025 | — | -$7.4M | — |
| Sep 30, 2025 | — | -$4.0M | — |
| Jun 30, 2025 | $2.7M | -$915.0K | -33.5% |
From Traws Pharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…